Published

04 Dec 25

Updated

10 Jul 26

Views

185

Not Invested

AbsciABSI

Fair Value

US$13.78

Share price10 Jul

US$9.5530.7% undervalued

1Y263.12%

7D4.03%

Endometriosis And Hair Loss Therapies Will Unlock Long-Term Value Through AI-Driven Biologic Development

AnalystConsensusTarget

Analyst Consensus Target compiles analysts opinions to create narratives on stocks using the Analysts Consensus Price Target, forecasted revenue and earnings figures, as well as the transcripts of earnings calls.

Published

04 Dec 25

Updated

10 Jul 26

Views

185

Not Invested

Shared on 10 Jul 26

Fair value Increased 11%

ABSI: Interim Hair Loss Data And Funding Will Drive Repricing Ahead

Early trial results for Absci’s ABS-201 in hair loss look encouraging, and a fresh funding raise gives the company more room to push the program forward. Analysts are lifting their views as expectations build for the next round of key readouts, but the path still hinges on whether the upcoming results hold up.

26 views

Shared on 26 Jun 26

Fair value Increased 53%

ABSI: Interim Hair Loss Data And Financing Will Drive Repricing Ahead

Early results from Absci’s hair-loss drug look encouraging, and a new cash raise eases worries about whether it can keep funding its plans. Analysts are now baking in bigger hopes for the same drug in other conditions too—making the next clinical updates a key moment that could swing sentiment either way.

19 views

Fair Value vs Share Price

US$13.78

vs US$9.5530.7% undervalued

165.9%

Revenue growth

18.9%

Profit margin

Recent News & Updates

No updates

Recent updates

No updates

Stay ahead on Absci

Fair value estimate changes
Narrative and analyst updates
Key company announcements

Company analysis

Flawless balance sheet with low risk.

Market capUS$1.6b

PB6.7x

Estimated Growth57.1%

Dividend YieldN/A

Full analysis

CEO & management

Sean McClain

CEO

3.2yrs

CEO Tenure

A clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States.